ANDA 216232, held by Micro Labs. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 216232 (Fluoxetine Hydrochloride), held by Micro Labs, was first approved by FDA on Mar 29, 2022, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 29, 2022 | Original application | Approved | None posted |
| Fluoxetine HydrochlorideEQ 10MG BASE · capsule;oral | Fluoxetine Hydrochloride | Discontinued |
| Fluoxetine HydrochlorideEQ 20MG BASE · capsule;oral | Fluoxetine Hydrochloride | Discontinued |
| Fluoxetine HydrochlorideEQ 40MG BASE · capsule;oral | Fluoxetine Hydrochloride | Discontinued |
| Nov 15, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 29, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters